{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:50:41Z","timestamp":1776387041309,"version":"3.51.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s11906-019-0909-z","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T09:15:06Z","timestamp":1547802906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antihypertensive Agents in the Dialysis Patient"],"prefix":"10.1007","volume":"21","author":[{"given":"Michelle A.","family":"Fravel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Bald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mony","family":"Fraer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"909_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000331067","volume":"34","author":"R Agarwal","year":"2011","unstructured":"Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34:381\u201390.","journal-title":"Am J Nephrol"},{"key":"909_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","volume":"115","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291\u20137.","journal-title":"Am J Med"},{"key":"909_CR3","doi-asserted-by":"publisher","unstructured":"Sarafidis PA, Mallamaci F, Loutradis C, Ekart R, Torino C, Karpetas A, et al. Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrol Dial Transplant. 2018. \n                      https:\/\/doi.org\/10.1093\/ndt\/gfy147\n                      \n                    .","DOI":"10.1093\/ndt\/gfy147"},{"key":"909_CR4","volume-title":"National Chronic Kidney Disease Fact Sheet, 2017","author":"Centers for Disease Control and Prevention","year":"2017","unstructured":"Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2017."},{"key":"909_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijcard.2008.12.104","volume":"142","author":"M Nishimura","year":"2010","unstructured":"Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. Int J Cardiol. 2010;142:80\u20136.","journal-title":"Int J Cardiol"},{"key":"909_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000099013","volume":"27","author":"YQ Tong","year":"2007","unstructured":"Tong YQ, Hou HM. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol. 2007;27:63\u20139.","journal-title":"Am J Nephrol"},{"key":"909_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000429274","volume":"41","author":"HJ Kornerup","year":"1984","unstructured":"Kornerup HJ, Schmitz O, Danielsen H, Pedersen EB, Giese J. Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contrib Nephrol. 1984;41:123\u20137.","journal-title":"Contrib Nephrol"},{"key":"909_CR8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","volume":"327","author":"RL Converse Jr","year":"1992","unstructured":"Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad- Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912\u20138.","journal-title":"N Engl J Med"},{"key":"909_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","volume":"106","author":"M Hausberg","year":"2002","unstructured":"Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974\u20139.","journal-title":"Circulation"},{"key":"909_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/jch.12017","volume":"14","author":"C Ott","year":"2012","unstructured":"Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens (Greenwich). 2012;14:799\u2013801.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"909_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/15701611113119990143","volume":"12","author":"V Papademetriou","year":"2014","unstructured":"Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P, Tsioufis C. Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol. 2014;12:47\u201354.","journal-title":"Curr Vasc Pharmacol"},{"key":"909_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/HJH.0000000000001283","volume":"35","author":"P Sarafidis","year":"2017","unstructured":"\u2022 Sarafidis P, Persub A, Agarwal R, Burnierf M, de Leeuwg P, Ferroi C, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association ^ European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the kidney working group of the European Society of Hypertension (ESH). J Hypertens. 2017;35:657\u201376 This position paper is a comprehensive review of management of hypertension in dialysis, including etiology, blood pressure measurement, suggested blood pressure targets, utilization of antihypertensive agents, recommended first and second-line therapies, and opportunities for future research.","journal-title":"J Hypertens"},{"key":"909_CR13","doi-asserted-by":"publisher","first-page":"E642","DOI":"10.1152\/ajpcell.1991.261.4.C642","volume":"261","author":"P Eggena","year":"1991","unstructured":"Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Phys. 1991;261:E642\u20136.","journal-title":"Am J Phys"},{"key":"909_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","volume":"61","author":"I Koulouridis","year":"2013","unstructured":"Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61:44\u201356.","journal-title":"Am J Kidney Dis"},{"key":"909_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","volume":"14","author":"H Schmid","year":"2009","unstructured":"Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14:185\u201390.","journal-title":"Eur J Med Res"},{"key":"909_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"Y Chiu","year":"2009","unstructured":"Chiu Y, Teitelbaum I, Misra M, de Leon E, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089\u201396.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"909_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/ki.2009.469","volume":"77","author":"NW Levin","year":"2010","unstructured":"\u2022 Levin NW, Kotanko P, Eckardt K, Kasiske BL, Chazot C, Cheung A, et al. Blood pressure in chronic kidney disease stage 5D \u2013 report from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2010;77(4):273\u201384. \n                      https:\/\/doi.org\/10.1038\/ki.2009.469\n                      \n                     This position paper is a comprehensive review of management of hypertension in dialysis, including etiology, blood pressure measurement, utilization of antihypertensive agents, and opportunities for future research.","journal-title":"Kidney Int"},{"key":"909_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.108.125674","volume":"53","author":"R Agarwal","year":"2009","unstructured":"Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53:500\u20137.","journal-title":"Hypertension"},{"key":"909_CR19","first-page":"655","volume":"15","author":"M Ozkahya","year":"2002","unstructured":"Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol. 2002;15:655\u201360.","journal-title":"J Nephrol"},{"key":"909_CR20","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2215\/CJN.03890416","volume":"11","author":"C Torino","year":"2016","unstructured":"Torino C, Gargani L, Sicari R, Letachowicz K, Ekart R, Fliser D, et al. The agreement between auscultation and lung ultrasound in hemodialysis patients: the LUST study. Clin J Am Soc Nephrol. 2016;11:2005\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"key":"909_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000326235","volume":"33","author":"R Agarwal","year":"2011","unstructured":"Agarwal R, Bouldin JM, Light RP, Garg A. Probing dry-weight improves left ventricular mass index. Am J Nephrol. 2011;33:373\u201380.","journal-title":"Am J Nephrol"},{"key":"909_CR22","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ndt\/gfn599","volume":"24","author":"M Kayikcioglu","year":"2009","unstructured":"Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant. 2009;24:956\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"909_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/j.1523-1755.2004.00876.x","volume":"66","author":"FM Paula de","year":"2004","unstructured":"de Paula FM, Peixoto AJ, Pinto LV, Dorigo D, Patricio PJ, Santos SF. Clinical consequences of an individualized dialysate sodium prescrip- tion in hemodialysis patients. Kidney Int. 2004;66:1232\u20138.","journal-title":"Kidney Int"},{"key":"909_CR24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.ajkd.2011.06.030","volume":"58","author":"MJ Munoz","year":"2011","unstructured":"Munoz MJ, Bayes LY, Sun S, Doss S, Schiller B. Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study. Am J Kidney Dis. 2011;58:956\u201363.","journal-title":"Am J Kidney Dis"},{"key":"909_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.2215\/CJN.02250507","volume":"2","author":"P Alborzi","year":"2007","unstructured":"\u2022\u2022 Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228\u201334 This prospective trial helped to establish the utility of home blood pressure measurement as an accurate means for monitoring blood pressure in ESRD based on correlation with cardiovascular outcomes.","journal-title":"Clin J Am Soc Nephrol"},{"key":"909_CR26","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/00004872-199917120-00013","volume":"17","author":"C Zoccali","year":"1999","unstructured":"Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giacone G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens. 1999;17:1751\u20138.","journal-title":"J Hypertens"},{"key":"909_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2215\/CJN.01891105","volume":"1","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2006;1:389\u201398.","journal-title":"Clin J Am Soc Nephrol"},{"key":"909_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1046\/j.1523-1755.1998.00005.x","volume":"54","author":"PG Zager","year":"1998","unstructured":"Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. \u2018U\u2019 curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561\u20139.","journal-title":"Kidney Int"},{"key":"909_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","volume":"373","author":"HJ Heerspink","year":"2009","unstructured":"\u2022\u2022 Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009\u201315 This meta-analysis, including nine clinical trials, was the first of its kind published to establish the cardiovascular benefit of antihypertensive agents in ESRD patients.","journal-title":"Lancet"},{"key":"909_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/HYPERTENSIONAHA.108.128116","volume":"53","author":"R Agarwal","year":"2009","unstructured":"\u2022\u2022 Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009;53:860\u20136 This meta-analysis, including five clinical trials, helped to confirm the cardiovascular benefit of antihypertensive agents in ESRD patients and highlighted potentially greater benefit in dialysis patients with hypertension specifically.","journal-title":"Hypertension"},{"key":"909_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"53","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, Marz W. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;53:238\u201348.","journal-title":"N Engl J Med"},{"key":"909_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395\u2013407.","journal-title":"N Engl J Med"},{"key":"909_CR33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"909_CR34","doi-asserted-by":"publisher","unstructured":"Mallappallil M, Fishbane S, Wanchoo R, Lerma E, Roche-Recinos A, Salifu M. Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists. BMC Nephrol 2018:19. \n                      https:\/\/doi.org\/10.1186\/s12882-018-0943-0\n                      \n                    .","DOI":"10.1186\/s12882-018-0943-0"},{"issue":"6","key":"909_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/hyp.0000000000000066","volume":"71","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71(6):1269\u2013324. \n                      https:\/\/doi.org\/10.1161\/hyp.0000000000000066\n                      \n                    .","journal-title":"Hypertension"},{"key":"909_CR36","volume-title":"Drug prescribing in renal failure: dosing guidelines for adults and children","author":"GR Aronoff","year":"2009","unstructured":"Aronoff GR. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2009.","edition":"5"},{"key":"909_CR37","volume-title":"Handbook of dialysis","author":"F Mallamaci","year":"2015","unstructured":"Mallamaci F, Zoccali C. Hypertension. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.","edition":"5"},{"key":"909_CR38","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.2215\/CJN.00870116","volume":"11","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Georgianos PI. Pharmacotherapy of hypertension in chronic dialysis patients. Clin J Am Soc Nephrol. 2016;11:2062\u201375. \n                      https:\/\/doi.org\/10.2215\/CJN.00870116\n                      \n                    .","journal-title":"Clin J Am Soc Nephrol"},{"key":"909_CR39","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","volume":"41","author":"G Cice","year":"2003","unstructured":"\u2022\u2022 Cice G, Ferrara L, D\u2019Andrea A, D\u2019Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo controlled trial. J Am Coll Cardiol. 2003;41:1438\u201344 This is one of very few prospective, randomized controlled, double blind studies examining antihypertensive agents in ESRD to find clinically and statistically significant benefit with treatment.","journal-title":"J Am Coll Cardiol"},{"key":"909_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/ndt\/gft515","volume":"29","author":"R Agarwal","year":"2014","unstructured":"Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29:672\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"909_CR41","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1046\/j.1523-1755.1999.00359.x","volume":"55","author":"R Agarwal","year":"1999","unstructured":"Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int. 1999;55:1528\u201335.","journal-title":"Kidney Int"},{"key":"909_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1681\/ASN.2014040324","volume":"26","author":"MA Weir","year":"2015","unstructured":"Weir MA, Dixon SN, Fleet JL, Roberts MA, Hackam DG, Oliver MJ, et al. Beta-blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26:987\u201396.","journal-title":"J Am Soc Nephrol"},{"key":"909_CR43","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","volume":"23","author":"M Tepel","year":"2008","unstructured":"\u2022\u2022 Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23:3605\u201312 This is one of very few prospective, randomized controlled, double blind studies examining antihypertensive agents in ESRD; clinically and statistically significant benefit with treatment was found.","journal-title":"Nephrol Dial Transplant"},{"key":"909_CR44","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","volume":"21","author":"A Takahashi","year":"2006","unstructured":"Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis \u2013 a randomized study. Nephrol Dial Transplant. 2006;21:2507\u201312.","journal-title":"Nephrol Dial Transplant"},{"key":"909_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.5414\/CNP69425","volume":"69","author":"M Leidig","year":"2008","unstructured":"Leidig M, Bambauer R, Kirchertz EJ, Szab\u00e3 T, Handrock R, Leinung D, et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008;69:425\u201332.","journal-title":"Clin Nephrol"},{"key":"909_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","volume":"52","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501\u20136.","journal-title":"Am J Kidney Dis"},{"key":"909_CR47","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/ajkd.2001.29221","volume":"38","author":"R Agarwal","year":"2001","unstructured":"Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis. 2001;38:1245\u201350.","journal-title":"Am J Kidney Dis"},{"key":"909_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000451067","volume":"44","author":"DA Bushinsky","year":"2016","unstructured":"Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44:404\u201310.","journal-title":"Am J Nephrol"},{"key":"909_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000441262","volume":"41","author":"AS Bomback","year":"2016","unstructured":"Bomback AS. Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif. 2016;41:166\u201370.","journal-title":"Blood Purif"},{"key":"909_CR50","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","volume":"63","author":"Y Matsumoto","year":"2014","unstructured":"Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"909_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jch.12628","volume":"18","author":"C Lin","year":"2016","unstructured":"Lin C, Zhang Q, Zhang H, Lin A. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo- controlled study. J Clin Hypertens (Greenwich). 2016;18:121\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"909_CR52","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2215\/CJN.12371214","volume":"10","author":"M Walsh","year":"2015","unstructured":"Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"909_CR53","unstructured":"Brest UH. ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST). \n                      ClinicalTrials.gov\n                      \n                    : Bethesda (MD): National Library of Medicine (US). 2018. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01848639\n                      \n                    . Accessed 7 Nov 2018."},{"key":"909_CR54","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1046\/j.1523-1755.2001.0590031128.x","volume":"59","author":"JF Medcalf","year":"2001","unstructured":"Medcalf JF, Harris K, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59:1128\u201333.","journal-title":"Kidney Int"},{"key":"909_CR55","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ajem.2016.05.042","volume":"34","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Guffey D, Minard C, Workeneh B. Efficacy of loop diuretics in the management of undocumented patients with end-stage renal disease. Am J Emerg Med. 2016;34:1552\u20135.","journal-title":"Am J Emerg Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-0909-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:17:39Z","timestamp":1579306659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-0909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-0909-z","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"18 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"5"}}